CRT unveils 'screen test' for potential drugs to treat oestrogen positive breast cancer

March 6, 2012

Cancer Research UK and its commercial arm, Cancer Research Technology have developed a unique test to discover molecules that could lead to potential new treatments for oestrogen receptor (ER)-positive breast cancer.

The team at Cancer Research UK’s Cambridge Research Institute has unveiled a cell-based test that allows scientists to screen a library of 150,000 small drug-like and identify those that switch off a cell signalling system called the FOXA1 pathway.

The team has previously shown that blocking the main protein in the pathway, FOXA1, blocks growth of ER-positive cells, even in the presence of oestrogen receptors, which usually fuel the disease.

Current standard hormone treatments block the oestrogen receptor or the production of oestrogen. But sometimes patients stop responding to these drugs.

Resistant ER-positive breast tumours often rely on cell signals triggered by the oestrogen receptor to continue to fuel the disease.

The discovery of molecules that block the FOXA1 pathway, which prevents the oestrogen receptor driving the cancer, might provide new approaches to treat patients who are resistant to current approaches.

Dr Jason Carroll, group leader at Cancer Research UK’s Cambridge Research Institute, said: “There’s an urgent need to find new ways to treat breast cancer that is no longer responding to standard treatments, which work by targeting the effect of oestrogen in cancer cells.

“Our team has pinpointed the FOXA1 pathway, which we can target with new treatments to help combat this problem.

“We’ve designed a tailored test that identifies the molecules which switch off the pathway – and which we hope could one day be developed into a new class of drugs.”

The team also discovered that blocking FOXA1 could prevent growth of molecular apocrine breast cancer cells.  Women with this form of breast cancer have limited options for treatment and poor survival.

Dr Keith Blundy, CEO of Cancer Research Technology, said: “We’re proud that the work of Cancer Research UK has already helped to transform breast cancer treatment, leading to significant improvements in survival.

“The FOXA1 pathway is an exciting new area of research and we hope that our cell-based screen will allow us to identify potential new targets for drug development this year.

“We’d be keen to collaborate with industry to screen their library, alongside ongoing research input from our team, to form an effective partnership with exciting opportunities.”

Explore further: Reprogrammed oestrogen binding linked to more aggressive breast cancer

Related Stories

Reprogrammed oestrogen binding linked to more aggressive breast cancer

January 4, 2012
(Medical Xpress) -- Scientists based at Cancer Research UK’s Cambridge Research Institute have discovered how receptors for the female sex hormone oestrogen attach to a different part of the DNA in breast cancer patients ...

Scientists find new drug target in breast cancer

May 22, 2011
Researchers have identified a new protein involved in the development of drug resistance in breast cancer which could be a target for new treatments, they report today in the journal Nature Medicine.

Scientists discover how antibiotic molecule found in bacteria stops breast cancer

August 22, 2011
(Medical Xpress) -- Scientists have discovered how a molecule that was first discovered in bacteria blocks a protein which causes breast cancer to develop and spread, reveals research published in Nature Chemistry today.

Lessening the impact of cancer-causing hormones

February 9, 2012
Increasing the production of proteins that help rid the body of toxins may play a crucial role in the fight against breast and prostate cancer, researchers from Flinders University believe.

New hope for advanced post-menopausal breast cancer patients resistant to hormonal therapy

September 26, 2011
Results from a phase III clinical trial have shown that combining two existing cancer drugs to treat post-menopausal women with advanced breast cancer resistant to hormonal therapy significantly improves outcome. Researchers ...

Recommended for you

Cancer-death button gets jammed by gut bacterium

July 27, 2017
Researchers at Michigan Medicine and in China showed that a type of bacterium is associated with the recurrence of colorectal cancer and poor outcomes. They found that Fusobacterium nucleatum in the gut can stop chemotherapy ...

Researchers release first draft of a genome-wide cancer 'dependency map'

July 27, 2017
In one of the largest efforts to build a comprehensive catalog of genetic vulnerabilities in cancer, researchers from the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute have identified more than 760 genes ...

Long-sought mechanism of metastasis is discovered in pancreatic cancer

July 27, 2017
Cells, just like people, have memories. They retain molecular markers that at the beginning of their existence helped guide their development. Cells that become cancerous may be making use of these early memories to power ...

Blocking the back-door that cancer cells use to escape death by radiotherapy

July 27, 2017
A natural healing mechanism of the body may be reducing the efficiency of radiotherapy in breast cancer patients, according to a new study.

Manmade peptides reduce breast cancer's spread

July 27, 2017
Manmade peptides that directly disrupt the inner workings of a gene known to support cancer's spread significantly reduce metastasis in a mouse model of breast cancer, scientists say.

Glowing tumor technology helps surgeons remove hidden cancer cells

July 27, 2017
Surgeons were able to identify and remove a greater number of cancerous nodules from lung cancer patients when combining intraoperative molecular imaging (IMI) - through the use of a contrast agent that makes tumor cells ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.